Display options
Cite
Olesiński T, Fijałkowska A, Rutkowski A. The safety of low-molecular-weight heparins in the prevention of venous thromboembolism in surgically-treated cancer patients: results of a multicentre observational study. Contemp Oncol (Pozn). 2017;21(2):152-156doi: 10.5114/wo.2017.68624.
Olesiński, T., Fijałkowska, A., & Rutkowski, A. (2017). The safety of low-molecular-weight heparins in the prevention of venous thromboembolism in surgically-treated cancer patients: results of a multicentre observational study. Contemporary oncology (Poznan, Poland), 21(2), 152-156. https://doi.org/10.5114/wo.2017.68624
Olesiński, Tomasz, et al. "The safety of low-molecular-weight heparins in the prevention of venous thromboembolism in surgically-treated cancer patients: results of a multicentre observational study." Contemporary oncology (Poznan, Poland) vol. 21,2 (2017): 152-156. doi: https://doi.org/10.5114/wo.2017.68624
Olesiński T, Fijałkowska A, Rutkowski A. The safety of low-molecular-weight heparins in the prevention of venous thromboembolism in surgically-treated cancer patients: results of a multicentre observational study. Contemp Oncol (Pozn). 2017;21(2):152-156. doi: 10.5114/wo.2017.68624. Epub 2017 Jun 30. PMID: 28947885; PMCID: PMC5611505.
Copy Download .nbib Format: NLM
Share it on

Contemp Oncol (Pozn). 2017;21(2):152-156. doi: 10.5114/wo.2017.68624. Epub 2017 Jun 30.

The safety of low-molecular-weight heparins in the prevention of venous thromboembolism in surgically-treated cancer patients: results of a multicentre observational study.

Contemporary oncology (Poznan, Poland)

Tomasz Olesiński, Anna Fijałkowska, Andrzej Rutkowski

Affiliations

  1. Department of Oncological Gastroenterology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
  2. Department of Cardiology, Mother and Child Institute, Warsaw, Poland

PMID: 28947885 PMCID: PMC5611505 DOI: 10.5114/wo.2017.68624

Abstract

AIM OF THE STUDY: Despite widespread use of pharmacological prophylaxis, venous thromboembolism (VTE) still constitutes a common complication in cancer patients. The aim of the study was to analyse the safety of low-molecular-weight heparins (LMWH) in the prevention of VTE in surgically-treated cancer patients.

MATERIAL AND METHODS: A total of 5207 cancer patients (44.5% men and 55.5% women) aged 16-97 years participated in a prospective observational study conducted in 13 Polish cancer centres in 2005-2008. This cohort included 4782 subjects who were treated surgically and received LMWH as a pharmacological prophylaxis for VTE prior to or after the surgery. The incidence of haemorrhagic complications and thrombocytopaenia was analysed in this cohort, along with intra-hospital mortality.

RESULTS: Mean duration of LMWH administration was 9.4 ±7.8 days. Haemorrhagic complications: heavy (

CONCLUSIONS: LMWH seems to be a safe form of pharmacological prophylaxis for VTE in surgically-treated cancer patients.

Keywords: low-molecular-weight heparins; pharmacological prophylaxis; venous thromboembolism

References

  1. Cochrane Database Syst Rev. 2014 Jun 19;(6):CD006649 - PubMed
  2. Cochrane Database Syst Rev. 2014 Aug 29;(8):CD008500 - PubMed
  3. J Thromb Haemost. 2011 Jul;9 Suppl 1:316-24 - PubMed
  4. Am J Cardiol. 1997 Oct 15;80(8):1066-9 - PubMed
  5. Cochrane Database Syst Rev. 2014 May 07;(5):CD003747 - PubMed
  6. Thromb Haemost. 2012 Apr;107(4):699-716 - PubMed
  7. Pol Arch Med Wewn. 2009;119 Suppl 1:1-69 - PubMed
  8. Semin Hematol. 2013 Jul;50(3):251-8 - PubMed
  9. Semin Thromb Hemost. 2006 Oct;32(7):651-8 - PubMed
  10. Chest. 1995 Oct;108(4):978-81 - PubMed
  11. Thromb Haemost. 2007 Oct;98(4):756-64 - PubMed
  12. Eur J Intern Med. 2013 Jul;24(5):433-9 - PubMed
  13. J Exp Clin Cancer Res. 2008 Jul 18;27:21 - PubMed
  14. Thromb Res. 2014 Dec;134(6):1214-9 - PubMed
  15. J R Soc Med. 1989 Apr;82(4):203-5 - PubMed
  16. JAMA. 2014 Sep 17;312(11):1122-35 - PubMed
  17. Chest. 1997 Oct;112(4):974-9 - PubMed

Publication Types